CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
The move will add new global talent to Cytel’s Strategic Consulting group
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
The company will address the observations within a stipulated timeline working with the regulators
This will be an added advantage for Supriya Lifescience Limited in the European market.
He is a seasoned professional having worked in reputed corporates in API business with over 35+ years of experience covering manufacturing, general management, and business
Sud has more than 32 years of work experience with different companies like Clivient, Jubilant Life Sciences, Piramal Enterprises, Parabolic Drugs, Orchid Chemicals and Pharmaceuticals, Ranbaxy Labs, and Lupin
Subscribe To Our Newsletter & Stay Updated
